Akebia Ther Company Insiders
AKBA Stock | USD 1.13 0.01 0.88% |
Akebia Ther employs about 167 people. The company is managed by 19 executives with a total tenure of roughly 27 years, averaging almost 1.0 years of service per executive, having 8.79 employees per reported executive. Analysis of Akebia Ther's management performance can provide insight into the company performance.
Steven Burke President Senior Vice President Chief Medical Officer |
Michel Dahan President Senior Vice President and Chief Business Officer |
Akebia |
Akebia Ther Management Team Effectiveness
The company has return on total asset (ROA) of (0.0837) % which means that it has lost $0.0837 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities.Akebia Ther Workforce Comparison
Akebia Ther is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 873. Akebia Ther retains roughly 167 in number of employees claiming about 19% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.23) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.44) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.44. Akebia Ther Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akebia Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akebia Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akebia Ther insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michel Dahan over two weeks ago Disposition of 34840 shares by Michel Dahan of Akebia Ther at 1.26 subject to Rule 16b-3 | ||
Nicole Hadas over two months ago Acquisition by Nicole Hadas of 200000 shares of Akebia Ther subject to Rule 16b-3 | ||
Steven Burke over three months ago Disposition of 7169 shares by Steven Burke of Akebia Ther at 1.58 subject to Rule 16b-3 | ||
John Butler over three months ago Disposition of 37733 shares by John Butler of Akebia Ther at 1.52 subject to Rule 16b-3 | ||
David Spellman over a year ago Sale by David Spellman of 63567 shares of Akebia Ther | ||
David Spellman over a year ago Sale by David Spellman of 75 shares of Akebia Ther |
Akebia Ther Notable Stakeholders
An Akebia Ther stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akebia Ther often face trade-offs trying to please all of them. Akebia Ther's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akebia Ther's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John MBA | President, CEO | Profile | |
Steven Burke | Senior Vice President Chief Medical Officer | Profile | |
Michel Dahan | Senior Vice President and Chief Business Officer | Profile | |
CGMA CPA | CFO VP | Profile | |
Nicole Hadas | Sr. VP, General Counsel and Secretary | Profile | |
Kristie Bolieau | VP Controller | Profile | |
Nicole JD | Chief VP | Profile | |
Mercedes Carrasco | Director Communications | Profile | |
David Spellman | CFO VP | Profile | |
Tracey Vetterick | Vice Administration | Profile | |
Thierry Bilbault | VP Devel | Profile | |
Douglas MBA | Vice Strategy | Profile | |
Nicholas Grund | Senior Officer | Profile | |
Carolyn Rucci | Senior Counsel | Profile | |
Kimberly Garko | Senior Officer | Profile | |
Meredith Bowman | Senior Officer | Profile | |
Steven MD | Senior Officer | Profile | |
Richard Malabre | Chief Officer | Profile | |
Violetta Cotreau | Chief VP | Profile |
About Akebia Ther Management Performance
The success or failure of an entity such as Akebia Ther often depends on how effective the management is. Akebia Ther management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akebia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akebia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people.
The data published in Akebia Ther's official financial statements typically reflect Akebia Ther's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Akebia Ther's quantitative information. For example, before you start analyzing numbers published by Akebia accountants, it’s essential to understand Akebia Ther's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Akebia Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akebia Ther's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akebia Ther's management manipulating its earnings.
Akebia Ther Workforce Analysis
Traditionally, organizations such as Akebia Ther use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akebia Ther within its industry.Akebia Ther Manpower Efficiency
Return on Akebia Ther Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 10.2M | |
Net Loss Per Employee | 310.9K | |
Net Loss Per Executive | 2.7M | |
Working Capital Per Employee | 109.5K | |
Working Capital Per Executive | 962.1K |
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |